Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody

Name
Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody
Accession Number
DBCAT003282
Description

Not Available

Drugs
DrugDrug Description
PalivizumabA monoclonal anti respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients.
NirsevimabA long-acting monoclonal antibody indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants.
Drugs & Drug Targets
DrugTargetType
PalivizumabFusion glycoprotein F0target
PalivizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
PalivizumabComplement C1r subcomponenttarget
PalivizumabComplement C1q subcomponent subunit Atarget
PalivizumabComplement C1q subcomponent subunit Btarget
PalivizumabComplement C1q subcomponent subunit Ctarget
PalivizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
PalivizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
PalivizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
NirsevimabFusion glycoprotein F0target
NirsevimabFusion glycoprotein F0target
NirsevimabFusion glycoprotein F0target